Accenture (NYSE: ACN) has acquired Bionest, a NYC-based consulting firm focused on Pharma, Biotech, Medical Device and Diagnostics.
The amount of the deal was not disclosed.
Bionest’s team of 46 scientifically-minded consultants, industry executives, and specialists based in NYC and in a European office in Paris, will join Accenture Strategy in the Life Sciences practice. Its focus on go-to-market strategy in life science’s most challenging areas will broaden and deepen Accenture’s capabilities through strategy development and operational execution.
Led by Rachel Laing, Ph.D., and Melinda Kutzing, Ph.D., Bionest is a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (CGT), and rare diseases. The firm helps clients navigate complex product development issues in order to drive growth, create value and gain competitive advantage and also offers expertise and analytic skills to support investors with due diligence assignments in these markets. Its track record includes more than 500 projects consisting of innovative, creative and differentiated action plans grounded in in-depth market and financial analysis.
Clients include both major established and emerging pharmaceutical and biotechnology brands, chiefly in North America and Europe.
FinSMEs
04/02/2023